BAY-1895344, an orally available, potent ATR (ataxia telangiectasia and Rad3-related) protein inhibitor (IC₅₀ = 7 nM). Displays potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride.